(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Recognize an Excellent Lab Precious stone - 2Investigating the Medical advantages of Aloe Vera
- 3Starbucks' new 'Bearista' cup is causing a stir — and is being listed on eBay for $600
- 47 Fast Approaches to Let loose Space on Your Telephone in a flash
- 5Overhaul Your Rest: Tips for a Serene Evening
- Holiday season sees uptick in norovirus cases, according to CDC
- Ski Resorts Universally: A Colder time of year Wonderland Guide
- In these U.S. groups, deaths now exceed births. What’s happening?
- Figure out How to Score Huge with Open Record Rewards
- Hamas delegation meets Egypt’s spy chief amid mutual ceasefire violation claims
- Creative Style: 10 Architects Reclassifying the Business
- Get away from the Tedious Drudgery: Go into Business Today!
- Italy's Beloved Trevi Fountain Hides A Unique Secret That Can Be Explored Underground
- Vote In favor of Your #1 sort of film
